| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071405 |
Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071805 |
Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071005 |
Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856072405 |
Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856072005 |
Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856070805 |
Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071205 |
Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071230 |
Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856070430 |
Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856070405 |
Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU |
Brand |
FDA |
07/13/2023 |
231.00 |
3907.33 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856070830 |
LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071030 |
LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071430 |
LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856071830 |
LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856072030 |
LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000076 |
Eisai Inc. |
09/30/2023 |
62856072430 |
LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply |
Brand |
FDA |
07/13/2023 |
1386.00 |
23444.00 |
02/23/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002143380 |
Trulicity Package Size: 4 Strength: 0.75 mg/0.5 mL Dosage Form: PEN INJECTOR |
Brand |
FDA |
01/01/2023 |
44.32 |
930.88 |
12/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002143480 |
Trulicity Package Size: 4 Strength: 1.5 mg/0.5 mL Dosage Form: PEN INJECTOR |
Brand |
FDA |
01/01/2023 |
44.32 |
930.88 |
12/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002223680 |
Trulicity Package Size: 4 Strength: 3.0 mg/0.5 mL Dosage Form: PEN INJECTOR |
Brand |
FDA |
01/01/2023 |
44.32 |
930.88 |
12/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002318280 |
Trulicity Package Size: 4 Strength: 4.5 mg/0.5 mL Dosage Form: PEN INJECTOR |
Brand |
FDA |
01/01/2023 |
44.32 |
930.88 |
12/07/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002481554 |
Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET |
Brand |
FDA |
01/01/2023 |
189.42 |
3633.42 |
12/15/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002533754 |
Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET |
Brand |
FDA |
01/01/2023 |
189.42 |
3633.42 |
12/15/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002621654 |
Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET |
Brand |
FDA |
01/01/2023 |
189.42 |
3633.42 |
12/15/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000114 |
Eli Lilly and Company |
03/31/2023 |
00002448354 |
Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET |
Brand |
FDA |
01/01/2023 |
189.42 |
3633.42 |
12/15/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087122501 |
Cetrotide Subcutaneous Kit 0.25 MG, 1 Each, Box |
Brand |
FDA |
01/26/2023 |
19.38 |
286.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087907001 |
Gonal-f Injection Solution Reconstituted 1050 UNIT, 1 Each, Unit-Dose, Vial |
Brand |
FDA |
01/26/2023 |
228.57 |
3381.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087903001 |
Gonal-f Injection Solution Reconstituted 450 UNIT, 1 Each, Unit-Dose, Vial |
Brand |
FDA |
01/26/2023 |
97.96 |
1449.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087111501 |
Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 300 UNIT/0.5ML, .5 ML, Unit-of-Use, Pen |
Brand |
FDA |
01/26/2023 |
65.31 |
966.04 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087111601 |
Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 450 UNT/0.75ML, .75 ML, Unit-of-Use, Pen |
Brand |
FDA |
01/26/2023 |
97.96 |
1449.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087111701 |
Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 900 UNIT/1.5ML, 1.5 ML, Unit-of-Use, Pen |
Brand |
FDA |
01/26/2023 |
195.92 |
2898.12 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087900501 |
Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT, 1 Each, Unit-Dose, Vial |
Brand |
FDA |
01/26/2023 |
16.33 |
241.51 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087900506 |
Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT, 1 Each, Unit-Dose, Vial Qty 10 |
Brand |
FDA |
01/26/2023 |
163.26 |
2415.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400000 |
Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
3199.70 |
94618.60 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400000 |
Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
3642.80 |
98261.40 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400004 |
Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
1279.88 |
37847.44 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400004 |
Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
1457.12 |
39304.56 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400005 |
Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
1599.85 |
47309.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400005 |
Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
1821.40 |
49130.70 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400006 |
Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
1919.82 |
56771.16 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400006 |
Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
2185.68 |
58956.84 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400007 |
Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
2239.79 |
66233.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400007 |
Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
2549.96 |
68782.98 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400008 |
Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
2559.76 |
75694.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400008 |
Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
2914.24 |
78609.12 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087400009 |
Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
2879.73 |
85156.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
09/30/2023 |
44087400009 |
Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box |
Brand |
FDA |
07/06/2023 |
3278.52 |
88435.26 |
11/23/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087115001 |
Ovidrel Subcutaneous Injectable 250 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
Brand |
FDA |
01/26/2023 |
14.73 |
217.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087332209 |
Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
Brand |
FDA |
01/26/2023 |
57.68 |
826.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087332201 |
Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087334409 |
Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
Brand |
FDA |
01/26/2023 |
57.68 |
826.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087334401 |
Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087018801 |
Rebif Rebidose Titration Pack Subcutaneous Solution Auto-injector 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087002209 |
Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
Brand |
FDA |
01/26/2023 |
57.68 |
826.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087002203 |
Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087004409 |
Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
Brand |
FDA |
01/26/2023 |
57.68 |
826.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087004403 |
Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087882201 |
Rebif Titration Pack Subcutaneous Solution Prefilled Syringe 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box |
Brand |
FDA |
01/26/2023 |
692.15 |
9920.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087000407 |
Serostim Subcutaneous Solution Reconstituted 4 MG, 1 Each, Unit-Dose, Vial Qty 7 |
Brand |
FDA |
01/26/2023 |
109.20 |
3228.68 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087000507 |
Serostim Subcutaneous Solution Reconstituted 5 MG, 1 Each, Unit-Dose, Vial Qty 7 |
Brand |
FDA |
01/26/2023 |
136.50 |
4035.85 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2023 |
44087000607 |
Serostim Subcutaneous Solution Reconstituted 6 MG, 1 Each, Unit-Dose, Vial Qty 7 |
Brand |
FDA |
01/26/2023 |
163.80 |
4843.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2023 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
Brand |
FDA |
04/01/2023 |
79.25 |
1713.17 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/21/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2023 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
Brand |
FDA |
10/01/2023 |
83.95 |
1797.12 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244001002 |
Edex®, Alprostadil For Inj Kit 10 MCG, 2 |
Brand |
FDA |
01/01/2023 |
9.11 |
160.87 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244001006 |
Edex®, Alprostadil For Inj Kit 10 MCG, 6 |
Brand |
FDA |
01/01/2023 |
27.32 |
482.66 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244002002 |
Edex®, Alprostadil For Inj Kit 20 MCG, 2 |
Brand |
FDA |
01/01/2023 |
11.76 |
207.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244002006 |
Edex®, Alprostadil For Inj Kit 20 MCG, 6 |
Brand |
FDA |
01/01/2023 |
35.29 |
623.43 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244004002 |
Edex®, Alprostadil For Inj Kit 40 MCG, 2 |
Brand |
FDA |
01/01/2023 |
16.06 |
283.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244004006 |
Edex®, Alprostadil For Inj Kit 40 MCG, 6 |
Brand |
FDA |
01/01/2023 |
48.19 |
851.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481002509 |
FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 |
Brand |
FDA |
01/01/2023 |
105.18 |
1167.59 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481068706 |
LIDODERM®, Lidocaine Patch 5%, 30 |
Brand |
FDA |
01/01/2023 |
71.63 |
795.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481062970 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 |
Generic |
FDA |
01/01/2023 |
307.77 |
3416.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481062770 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 |
Generic |
FDA |
01/01/2023 |
155.66 |
1728.02 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481062370 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 |
Generic |
FDA |
01/01/2023 |
217.86 |
2418.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481062385 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 |
Generic |
FDA |
01/01/2023 |
1061.91 |
11788.29 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
63481062870 |
PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 |
Generic |
FDA |
01/01/2023 |
235.37 |
2612.87 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244010010 |
THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 |
Generic |
FDA |
01/01/2023 |
28.86 |
320.35 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244020010 |
THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 |
Generic |
FDA |
01/01/2023 |
42.89 |
476.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244030010 |
THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 |
Generic |
FDA |
01/01/2023 |
52.71 |
585.16 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2023 |
52244040010 |
THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 |
Generic |
FDA |
01/01/2023 |
74.17 |
823.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2023 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
Brand |
FDA |
04/01/2023 |
391.74 |
8468.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/21/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2023 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
Brand |
FDA |
10/01/2023 |
410.74 |
8879.53 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/24/2024, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2023 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
Brand |
FDA |
04/01/2023 |
228.95 |
6099.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
12/31/2023 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
Brand |
FDA |
10/01/2023 |
237.88 |
6337.27 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. |
| Rx0000405 |
Esperion |
03/31/2023 |
72426011803 |
Nexletol 30 Tab 180 mg/1 Tablet Film Coated |
Brand |
FDA |
01/01/2023 |
11.53 |
395.96 |
12/03/2025 |
Single Source Drug |
None |
1 |
Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000405 |
Esperion |
03/31/2023 |
72426081803 |
Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated |
Brand |
FDA |
01/01/2023 |
11.53 |
395.96 |
03/14/2036 |
Single Source Drug |
None |
1 |
Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000104 |
EUSA Pharma (US) LLC |
06/30/2023 |
73090042001 |
Siltuximab For IV Infusion 100 MG, 1 Each, Unit-Dose, Vial |
Brand |
FDA |
04/01/2023 |
92.86 |
1419.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000104 |
EUSA Pharma (US) LLC |
06/30/2023 |
73090042101 |
Siltuximab For IV Infusion 400 MG, 1 Each, Unit-Dose, Vial |
Brand |
FDA |
04/01/2023 |
371.44 |
5677.48 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000329 |
Evoke Pharma, Inc. |
12/31/2023 |
72089030715 |
METOCLOPRAMIDE HYDROCHLORIDE 1 BOTTLE, PUMP in 1 CARTON (72089-307-15) / 9.8 mL in 1 BOTTLE, PUMP |
Brand |
FDA |
12/27/2023 |
190.00 |
2113.00 |
05/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000485 |
Exela Pharma Sciences, LLC |
03/31/2023 |
51754100703 |
ELCYS INFUSION 10 VIAL 10 ML 500 MG |
Brand |
FDA |
01/01/2023 |
123.53 |
947.03 |
01/15/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |